Professor Eyad Elkord has a professor position at the Department of Biosciences and Bioinformatics, and he is the director of Suzhou Municipal Key Lab of Biomedical Sciences and Translational Immunology at the School of Science, Xi'an Jiaotong-Liverpool University, Suzhou, China. In addition,he is an Honorary Professor at University of Salford, UK. Before joining XJTLU, he was a Professor of Immunology with the Department of Applied Biology, College of Science, University of Sharjah, United Arab Emirates.

After obtaining his PhD in Tumor Immunology from University of Wales College of Medicine, Cardiff University (UK), he worked as a Postdoctoral Scientist (Jan 2005 - Dec 2007) at the Paterson Institute for Cancer Research, University of Manchester (UK), and was then promoted to a Research Fellow/Group Leader of the Clinical Immunotherapy Laboratory at the University of Manchester (Jan 2008 - Nov 2010). He then undertook a Lecturer position with the University of Salford (Dec 2010 - July 2012) and was promoted in August 2012 to a Senior Lecturer. He moved to the College of Medicine & Health Science, United Arab Emirates University, in 2012 and was an Associate Professor of Immunology until September 2016. He then worked as a Principal Investigator at Qatar Biomedical Research Institute and a Professor at Hamad Bin Khalifa University, Qatar (July 2016 - Nov 2020) and he also had an Honorary Professor position at the Institute of Cancer Sciences-University of Manchester, UK.

Professor Elkord is a member of several highly regarded scientific societies and an editorial board member for peer-reviewed international journals such as Frontiers in Immunology & Oncology (specialty Cancer Immunity & Immunotherapy), BMC Cancer, Vaccines, Heliyon and Journal of Immunology Research. He is the Editor-in-Chief for the newly established journal "Cancer Immunology Connect". He is a reviewer to many international journals and well-known funding agents, such as the UK Medical Research Council, European Research Council, Dutch Research Council. Dr Elkord has more than 145 publications in peer-reviewed high-impact international journals with more than 13300 citations and an h-index of 48 and M-index of 2.7. In recognition of his research influence, Prof. Elkord has been named in Stanford University’s yearly and career global lists of the top 2% of scientists for five consecutive years (2019-2023), achieving the position in the top 0.26% in the Immunology subfield. He was also recognized by Elsevier among the Most Highly Cited Chinese Researchers of 2024.

BIO309 Molecular Immunology (Year 4), Coordinator, 2024-present.

BIO002 Introductory Biology (Year 1), 2024-present

BIO303 Final Year Project (Year 4),2024-present

BIO406 MRES project, 2024-present

• Recognized by Elsevier among the Most Highly Cited Chinese Researchers of 2024.
• Named in Stanford University’s global list of top 2% of influential Scientists for five consecutive years (2019-2023).
• Special Issue Guest Editor, Seminars in Cancer Biology, Resistance Mechanisms to Cancer Immunotherapy, 2020.

• UAE University Award for Excellence in Scholarship, academic year 2015-2016.
• Certificate of achievement for publishing in top journals and bringing recognition to UAE University for 2013, 2014 and 2015.
• Winner of Dean’s Annual Research Prize, College of Science and Technology, University of Salford, June 2012.